

ACSM2A Antibody - C-terminal region

Rabbit Polyclonal Antibody

Catalog # AI15550

Product Information

Application	WB
Primary Accession	Q08AH3
Other Accession	NM_001010845 , NP_001010845
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine
Predicted	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	64223

Additional Information

Gene ID	123876
Alias Symbol	A-923A4.1, ACSM2
Other Names	Acyl-coenzyme A synthetase ACSM2A, mitochondrial, 6.2.1.2, Acyl-CoA synthetase medium-chain family member 2A, Butyrate--CoA ligase 2A, Butyryl-coenzyme A synthetase 2A, Middle-chain acyl-CoA synthetase 2A, ACSM2A, ACSM2, MACS2
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-ACSM2A antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	ACSM2A Antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	ACSM2A
Synonyms	ACSM2, MACS2
Function	Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism (By similarity). Capable of activating medium-chain fatty acids (e.g. butyric (C4) to decanoic (C10) acids), and certain carboxylate-containing xenobiotics, e.g. benzoate (By similarity).
Cellular Location	Mitochondrion {ECO:0000250 UniProtKB:Q68CK6}.

References

Ota T.,et al.Nat. Genet. 36:40-45(2004).
Martin J.,et al.Nature 432:988-994(2004).
Loftus B.J.,et al.Genomics 60:295-308(1999).
Kochan G.,et al.J. Mol. Biol. 388:997-1008(2009).
Iwai N.,et al.Hypertension 41:1041-1046(2003).

Images



Host: Rabbit
Target Name: ACSM2A
Sample Tissue: ACHN Whole cell lysate
S
Antibody Dilution: 1.0µg/ml

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.